Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
NRIXthis companyNurix Therapeutics, Inc.	$15.81	-5.54×	2.72×	17.45×	-5.2×	-213.0%	77.5%	-340.2%	-314.9%	-49.1%	-47.3%	-18.0%	0.1×	0.78×	0×	7.02×	0.0%	7	9.1	4	A-
CCCCC4 Therapeutics, Inc.	$3.12	-1.5×	0.62×	4.4×	-1.4×	-187.2%	77.8%	-290.7%	-292.1%	-40.9%	-31.4%	-62.7%	0.23×	0.14×	0×	7.81×	0.0%	3	-1.03	2	C
KURAKura Oncology, Inc.	$7.56	-3.27×	5.23×	13.5×	-2.84×	72.0%	99.9%	-449.9%	-412.9%	-160.0%	-48.8%	-7.8%	0.12×	0.47×	-200.81×	6.06×	0.0%	3	-2.79	2	C
KYMRKymera Therapeutics, Inc.	$134.33	-21.09×	4.16×	167.51×	-20.76×	-99.8%	100.0%	-891.3%	-794.4%	-19.7%	-20.9%	-3.6%	0.05×	0.91×	-1,403.21×	10.47×	0.0%	4	41.46	1	C-
RIGLRigel Pharmaceuticals, Inc.	$41.32	2.1×	1.97×	2.62×	5.95×	-171.8%	93.3%	42.6%	124.7%	93.8%	28.2%	9.8%	0.14×	0.1×	17.14×	2.42×	0.0%	4	4.57	4	A
RVMDRevolution Medicines, Inc.	$196.80	-13.39×	9.28×	0×	-13.68×	-99.5%	0.0%	0.0%	0.0%	-69.3%	-56.8%	-6.0%	0.1×	0.21×	-48.8×	7.14×	0.0%	1	12.52	1	C-
Peer median	—	-3.27×	4.16×	4.4×	-2.84×	-99.8%	93.3%	-290.7%	-292.1%	-40.9%	-31.4%	-6.0%	0.12×	0.21×	-48.8×	7.14×	0.0%	3	4.57	2	—